Stocktoria
Aquestive Therapeutics, Inc. AQST
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2018-07-25
Aquestive Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $44.5M | $57.6M | $50.6M | $47.7M | $50.8M |
| R&D expense | $17.2M | $20.3M | $13.1M | $17.5M | $17.0M |
| SG&A expense | $79.8M | $50.2M | $31.8M | $52.9M | $53.5M |
| Operating income | -$71.1M | -$30.8M | -$15.1M | -$42.1M | -$34.7M |
| Interest expense | — | — | $6.3M | $6.6M | $10.0M |
| Income tax | $0 | -$14,000 | $245,000 | $0 | $0 |
| Net income | -$83.8M | -$44.1M | -$7.9M | -$54.4M | -$70.5M |
| EPS (diluted) | $-0.78 | $-0.51 | $-0.13 | $-1.12 | $-1.85 |
| Operating cash flow | -$52.4M | -$35.8M | -$6.4M | -$9.8M | -$33.0M |
| Free cash flow | -$53.0M | -$35.9M | -$7.4M | -$10.8M | -$33.9M |
| Cash & equivalents | $121.2M | $71.5M | $23.9M | $27.3M | $28.0M |
| Inventory | $6.2M | $6.0M | $6.8M | $5.8M | $4.0M |
| Total assets | $160.4M | $101.4M | $57.4M | $57.1M | $62.0M |
| Total liabilities | $194.1M | $161.6M | $163.9M | $175.6M | $144.1M |
| Shareholders' equity | -$33.7M | -$60.2M | -$106.5M | -$118.6M | -$82.1M |
Source: SEC EDGAR filings · CIK 0001398733 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.